EGFR tyrosine kinase inhibitors and multidrug resistance: Perspectives

Frontiers in Bioscience

Volumn 16, Issue 5, 2011, Pages 1811-1823

  Colabufo, Nicola A ^a   Contino, Marialessandra ^a   Niso, Mauro ^a   Berardi, Francesco ^a   Leopoldo, Marcello ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

EGFR; L858R; MDR; Review; T790M; TKIs

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GLYCOPROTEIN P; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955001706     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3823     Document Type: Article

References (80)

1. A. S. Goustin, E. B. Leof, G. D. Shipley and H. L. Moses: Growth factors and cancer. Cancer Res. 46, 1015-1029 (1986) (Pubitemid 16048224)
2. S. A. Aaronson: Growth factors and cancer. Science 254, 1146-1153 (1991) (Pubitemid 21917439)
3. N. E. Hynes and H. A. Lane: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005) (Pubitemid 40637826)
4. Y. Yarden and M. X. Silwkowski: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127-137 (2001) (Pubitemid 33674041)
5. J. Marshall: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107, 1207-1278 (2006)
6. M. Scaltriti and J. Baselga: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer. Res. 12, 5268-5272 (2006) (Pubitemid 44497237)
7. I. Uberall, Z. Kolar, R. Trojanec, J. Berkovcova and M. Hajduch: The status and role of ErbB receptors in human cancer. Exp. Mol. Pathol. 84, 79-89 (2008)
8. O. Dassonville, A. Bozec, J. L. Fischel and G. Milano: EGFR targeting therapies: monoclonal antibodies versus Tyrosine Kinase inhibitors: similarities and differences. Crit. Rev. Oncol. Hematol. 62, 53-61 (2007) (Pubitemid 46330798)
9. P.G. Adams and M.W. Louis: Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-57 (2005).
10. F. Ciardiello: Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 1, 221-234 (2005)
11. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Y. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. P. Dong and J. Baselga: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21, 2237-46 (2003) (Pubitemid 46621858)
12. M. Reck and U. Gatzemeier: Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. Respir. Med. 99, 298-307 (2005) (Pubitemid 40267946)
13. R. S. Herbst: Erlotinib. (Tarceva): an update on the clinical trial program. Semin. Oncol. 30, 34-46 (2003) (Pubitemid 36828626)
14. J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer and R. L. Comis: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Evaluating antiangiogenesis agents in the clinic. Clin. Cancer Res. 10, 1206-11 (2004) (Pubitemid 38365208)
15. W. S. Siegel-Lakhai, J. H. Beijnen and J. H. Schellens: Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10, 579-89 (2005) (Pubitemid 41429121)
16. C. L. Arteaga: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19, 32S-40S (2001) (Pubitemid 32880077)
17. M. H. Cohen, G. A. Williams, Sridhara, G. Chen and R. Pazdur: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303-306 (2003) (Pubitemid 36929716)
18. M. H. Cohen, J. R. Johnson, Y. F. Chen, R. Sridhara and R. Pazdur: FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10, 461-466 (2005) (Pubitemid 41266326)
19. A. J. Tevaarwerk and J. M. Kolesar: Lapatinib: a smallmolecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin. Ther.31 Pt 2:2332-48. (2009)
20. R. G. Deeley, C. Westlake and S. P. Cole: Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86, 849-99 (2006) (Pubitemid 44033384)
21. P. Laurent-Puig, A. Lievre and H. Blons: Mutations and response to Epidermal Growth Factor Receptor inhibitors. Clinical Cancer Res. 15: 1133-1139 (2009)
22. M. M. Gottesman, T. Fojo and S. E. Bates: Multidrug resistance in cancer: role of ATPdependent transporters. Nat. Rev. Cancer 2, 48-58 (2002) (Pubitemid 37328807)
23. M. Dean, A. Rzhetsky and R. Allikmets: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11, 1156-1166 (2001) (Pubitemid 32677289)
24. C. F. Higgins: ABC transporters: from microorganisms to man. Ann. Rev. Cell Biol. 8, 67-113 (1992) (Pubitemid 23000992)
25. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan and M. M. Gottesman: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. 39, 361-398 (1999) (Pubitemid 29222564)
26. S. P. Cole, K. E. Sparks, K. Fraser, D. W. Loe, C. E. Grant, G. M. Wilson and R. G. Deeley: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54, 5902-5910 (1994) (Pubitemid 24375226)
27. A. H. Schinkel and J. W. Jonker. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3-29 (2003) (Pubitemid 36078452)
28. H. Burger, H. van Tol, A. W. Boersma, M. Brok, E. A. Wiemer, G. Stoter, K. Nooter. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104, 2940-2942 (2004) (Pubitemid 39434984)
29. N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Várady, O. Ujhelly, K. Szabó, L. Homolya, A. Váradi, L. Buday, G. Kéri, K. Német and B. Sarkadi: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res. 65, 17701777 (2005)
30. Z. Shi, A. K. Tiwari, S. Shukla, R. W. Robey, I. W. Kim, S. Parmar, S. E. Bates, Q. S. Si, C. S. Goldblatt, I. Abraham, L. W. Fu, S. V. Ambudkar, Z. S. Chen: Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem. Pharmacol. 77, 781-793 (2009)
31. Z. Shi, X. X. Peng, I. W. Kim, S. Shukla, Q. S. Si, R. W. Robey, S. E. Bates, T. Shen, C. R. Jr Ashby, L. W. Fu, S. V. Ambudkar and Z. S. Chen: Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATPbinding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67, 11012-11020 (2007) (Pubitemid 350145931)
32. C. L. Dai, A. K. Tiwari, C. P. Wu, X. D. Su, S. R. Wang, D. G. Liu, C. R. Jr Ashby, Y. Huang, R. W. Robey, Y. J. Liang, L. M. Chen, C. J. Shi, S. V. Ambudkar, Z. S. Chen and L. W. Fu: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68, 7905-7914 (2008)
33. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen and B. Halmos: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005) (Pubitemid 40271173)
34. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris and H. Varmus: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73. (2005)
35. R. Rosell, T. Morán, E. Carcereny, V. Quiroga, M. Á. Molina, C. Costa, S. Benlloch and M. Tarón: Non-smallcell lung cancer harbouring mutations in the EGFR kinase domain. Clin. Transl. Oncol. 12, 75-80 (2010)
36. R. Mulloy, A. Ferrand, Y. Kim, R. Sordella, D. W. Bell, D. A. Haber, K. S. Anderson and J. Settleman: Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67, 2325-2330 (2007) (Pubitemid 46424253)
37. L. Regales, M. N. Balak, Y. Gong, K. Politi, A. Sawai, C. Le, J. A. Koutcher, D. B. Solit, N. Rosen, M. F. Zakowski and W Pao: Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2:e810 (2007)
38. I. B. Weinstein and A. Joe: Oncogene addiction. Cancer Res. 68, 3077-3080 (2008)
39. A. F. Gazdar, H. Shigematsu, J. Herz and J. D. Minna: Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol. Med. 10, 481-486 (2004) (Pubitemid 39303620)
40. J. A. Engelman, P. A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson and L. C. Cantley LC: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. U S A 102, 3788-3793 (2005) (Pubitemid 40354690)
41. M. W. Karaman, S. Herrgard, D. K. Treiber, P. Gallant, C. E. Atteridge, B. T. Campbell, K. W. Chan, P. Ciceri, M. I. Davis, P. T. Edeen, R. Faraoni, M. Floyd, J. P. Hunt, D. J. Lockhart, Z. V. Milanov, M. J. Morrison, G. Pallares, H. K. Patel, S. Pritchard, L. M. Wodicka, P. P. Zarrinkar. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008)
42. K. Suda, R. Onozato, Y. Yatabe andT. Mitsudomi: EGFR T790M mutation a double role in lung cancer cell serviva? J. Thoracic Onc. 4, 1-4 (2009)
43. P. Giménez-Bonafé, A. Guillén Canovas, S. Ambrosio, A. Tortosa, R. and Pérez-Tomás: Drugs modulating MDR. In Multidrug Resistance : Biological and Pharmaceutical Advance in the Antitumour Treatment; Colabufo, N. A., Ed.; Research Signpost: Kerala (India), pp 63-99 (2008)
44. N. A. Colabufo, F. Berardi, M. Cantore, M. Contino, C. Inglese, M. Niso and R. Perrone: Perspectives of Pglycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological and diagnostic potentials. J. Med. Chem. 53, 1883-1897 (2010)
45. S. Nobili and E. Mini Overcoming Multidrug Resistance: Alternative approaches to P-glycoprotein modulators. In Multidrug Resistance : Biological and Pharmaceutical Advance in the Antitumour Treatment; Colabufo, N. A., Ed.; Research Signpost: Kerala (India), pp 101-139 (2008)
46. S. Dedhar, G. E. Hannigan, J. Rak and R. S. Kerbel. The extracellular environment and cancer. In: Tannock, I.F.; Hill Rp (eds) The Basic Science of Oncology, 3rd Edition, McGraw-Hill, New York, pp 198-218 (1998)
47. L. D. Mayer and J. A. Shabbits: The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 20, 87-93 (2001) (Pubitemid 34074683)
48. J. W. Pearson, W. E. Fogler, K. Volker, N. Usui, S. K. Goldenberg, E. Gruys, C.W. Riggs, K. Komschlies, R. H. Wiltrout, T. Tsuruo, I. Pastan, M. M. Gottesman and D. L. Longo: Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J. Natl. Cancer Inst. 83, 1386-1391 (1991)
49. D. Milojkovic and J. Apperley: Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin. Cancer Res. 15, 7519-7527 (2009)
50. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L. R. Chirieac, R. F. Padera, G. I. Shapiro, A. Baum, F Himmelsbach, W. J. Rettig, M. Meyerson, F. Solca, H. Greulich and K. K. Wong: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer mode. Oncogene 27:4702-4711 (2008).
51. J. A. Engelman, K. Zejnullahu, C. M. Gale, E. Lifshits, A. J. Gonzales, T. Shimamura, F. Zhao, P. W. Vincent, G. N. Naumov, J. E. Bradner, I. W. Althaus, L. Gandhi, G. I. Shapiro, J. M. Nelson, J. V. Heymach, M. Meyerson, K. K. Wong and P. A. Jänne: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67:11924-11932 (2007).
52. D. Li, T. Shimamura, H. Ji, L. Chen, H. J. Haringsma, K. McNamara, M. C. Liang, S. A. Perera, S. Zaghlul, C. L. Borgman, S. Kubo, M. Takahashi, Y. Sun, L. R. Chirieac, R. F. Padera, N. I. Lindeman, P. A. Jänne, R. K. Thomas, M. L. Meyerson, M. J. Eck, J. A. Engelman, G. I. Shapiro and K. K. Wong: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12:81-93 (2007) (Pubitemid 47001787)
53. F. X. Mahon, S. Hayette, V. Lagarde, F. Belloc, B. Turcq, F. Nicolini, C. Belanger, P. W. Manley, C. Leroy, G. Etienne, S. Roche and J. M. Pasquet: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 68, 9809-9816 (2008)
54. C. H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K. K. Wong, M. Meyerson, M. J. Eck. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U S A 105, 2070-2075 (2008) (Pubitemid 351439466)
55. S. B. Gendreau, R. Ventura, P. Keast, A. D. Laird, F. M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, F. Chu, L. Jackman, Y. Shi, P. Yu, J. Wang, D. T. Aftab, C. T. Jaeger, S. M. Meyer, A. De Costa, K. Engell, J. Chen, J. F. Martini and A. H. Joly: Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res.13, 3713-3723 (2007) (Pubitemid 46955136)
56. N. Godin-Heymann, L. Ulkus, B. W. Brannigan, U. McDermott, J. Lamb, S. Maheswaran, J. Settleman and D. A. Haber: The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther.7, 874-879 (2008). (Pubitemid 351551040)
57. K. G. Petrov, Y. M. Zhang, M. Carter, G. S. Cockerill, S. Dickerson, C. A. Gauthier, Y. Guo, R. A. Jr Mook, D. W. Rusnak, A. L. Walker, E. R. Wood and K. E. Lackey: Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg. Med. Chem. Lett. 16, 4686-4691 (2006) (Pubitemid 44094055)
58. Y. M. Zhang, S. Cockerill, S. B. Guntrip, D. Rusnak, K. Smith, D. Vanderwall, E. Wood and K. Lackey: Synthesis and SAR of potent EGFR/erbB2 dual inhibitors. Bioorg. Med. Chem. Lett. 14, 111-114 (2004) (Pubitemid 38010204)
59. P. Ballard, R. H. Bradbury, C. S. Harris, L. F. Hennequin, M. Hickinson, J. G. Kettle, J. Kendrew, T. Klinowska, D. J. Ogilvie, S. E. Pearson, E. J. Williams and I. Wilson: Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bioorg. Med. Chem. Lett. 16, 4908-4912 (2006) (Pubitemid 44209131)
60. A. Telliez, M. Desroses, N. Pommery, O. Briand, A. Farce, G. Laconde, A. Lemoine, P. Depreux and J. P. Henichart: Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells. ChemMedChem, 2, 318-332 (2007)
61. S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe and S. Sone: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-9487 (2008)
62. X. Wu, M. Li, Y. Qu, W. Tang, Y. Zheng, J. Lian, M. Ji and L. Xu: Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg. Med. Chem. 18, 3812-22 (2010)
63. A. T. Remaley, S. Rust, M. Rosier, C. Knapper, L. Naudin, C. Broccardo, K. M. Peterson, C. Koch, I. Arnould, C. Prades, N. Duverger, H. Funke, G. Assman, M. Dinger, M. Dean, G. Chimini, S. Santamarina-Fojo, D. S. Fredrickson, P. Denefle, H. Bryan and H. B. Brewer: Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc. Natl. Acad. Sci. U.S.A. 96, 12685-12690 (1999) (Pubitemid 29513563)
64. A. Brooks-Wilson, M. Marcil, S. M. Clee, L. H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. Molhuizen, O. Loubser, B. F. Ouelette, K. Fichter, K. J. Ashbourne-Excoffon, C. W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S. Pimstone, J. J. Kastelein, J. Genest and M. R. Hayden: Mutations in ABC1 in Tangier disease and familial highdensity lipoprotein deficiency. Nat. Genet. 22, 336-345 (1999) (Pubitemid 29369523)
65. S. E. Bates, S. Bakke, M. Kang, R. W. Robey, S. Zhai, P. Thambi, C. C. Chen, S. Patil, T. Smith, S. M. Steinberg, M. Merino, B. Goldspiel, B. Meadows, W. D. Stein, P. Choyke, F. Balis, W. D. Figg, T. Fojo: A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin. Cancer Res. 10, 4724-4733 (2004) (Pubitemid 38955523)
66. H. Minderman, K. L. O'Loughlin, L. Pendyala, M. R. Baer: VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10, 1826-1834 (2004) (Pubitemid 38435574)
67. E. Schneider, D. Paul, P. Ivy, K. H. Cowan: Multidrug resistance. Cancer Chemother. Biol. Response Modif. 18, 152-177 (1999)
68. A. S. Planting, P. Sonneveld, A. van der Gaast, A. Sparreboom, M. E. van der Burg, G. P. Luyten, K. de Leeuw, M. de Boer-Dennert, P. S. Wissel, R. C. Jewell, E. M. Paul, N. B. Jr. Purvis and J. Verweij: A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 55, 91-99 (2005) (Pubitemid 40064500)
69. L. Pusztai, P. Wagner, N. Ibrahim, E. Rivera, R. Theriault, D. Booser, F. W. Symmans, F. Wong, G. Blumenschein, D. R. Fleming, R. Rouzier, G. Boniface and G. N. Hortobagyi: Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapyresistant, advanced breast carcinoma. Cancer 104, 682-691 (2005) (Pubitemid 41114904)
70. L. van Zuylen, A. Sparreboom, A. van der Gaast, M. E. van der Burg, V. van Beurden, C. J. Bol, R. Woestenborghs, P. A. Palmer, J. Verweij: The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6, 1365-1371 (2000) (Pubitemid 30226221)
71. J. Robert and C Jarry: Multidrug resistance reversal agents. J. Med. Chem. 46, 4805-4817 (2003) (Pubitemid 37352018)
72. A. H. Dantzig, D. P. de Alwisa and M. Burgess: Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55, 133-150 (2003) (Pubitemid 36078455)
73. E. Teodori, S. Dei, C. Martelli, S. Scapecchi and F. Gualtieri: The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7, 893-909 (2006)
74. G. Bartolini, M. Orlandi, A. Papi, K. Ammar, F. Guerra, A. M. Ferreri and P. Rocchi: A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. In vivo 20, 729-733 (2006)
75. C. Hirayama, H. Watanabe, R. Nakashima, T. Nanbu, A. Hamada, A. Kuniyasu, H. Nakayama, T. Kawaguchi and H. Saito: Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinibresistance in K562 cells. Pharm. Res. 25, 827-835 (2008) (Pubitemid 351661829)
76. K. Imai and A. Takaoka: Comparingantibodyand smallmolecule therapies for cancer. Nat. Rev. Cancer 6, 714-727 (2006)
77. W. Xia, J. Bisi, J. Strum, L. Liu, K. Carrick, K. M. Graham, A. L. Treece, M. A. Hardwicke, M. Dush, Q. Liao, R. E. Westlund, S. Zhao, S. Bacus and N. L. Spector: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 66, 1640-1647 (2006) (Pubitemid 43259948)
78. A. Ocana, R. Serrano, R. Calero and A. Pandiella: Novel tyrosine kinase inhibitors in the treatment of cancer. Curr Drug Targets 10, 575-576 (2009)
79. M. S. Cohen, C. Zhang, K. M. Shokat and J. Taunton: Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005) (Pubitemid 40746129)
80. H. J. Burstein, Y. Sun, L. Y. Dirix, Z. Jiang, R. Paridaens, A. R. Tan, A. Awada, A. Ranade, S. Jiao, G. Schwartz, R. Abbas, C. Powell, K. Turnbull, J. Vermette, C. Zacharchuk and R. Badwe: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301-1307 (2010)